AUROBAC THERAPEUTICS’ pipeline stands out for its commitment to tackling the highest unmet medical needs in the fields of AMR, infectious diseases and their consequences. We focus on ESKAPE pathogens, and particularly the gram-negatives such as Pseudomonas aeruginosa, and on acute hospital settings where there are no satisfactory therapeutic options to date such as Acute Respiratory Infections (HAP, VAP), Sepsis and/or Septic Shock. New treatment modalities and classes that can be combined with rapid and actionable diagnostic to follow a precision medicine concept are our priorities.
AUROBAC THERAPEUTICS aims to cover the entire value chain of projects, including research and development, clinical trials, registration, and commercialization.
Pipeline will be released shortly